MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Free Cash flow
-$46,117K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Maturities of marketable securit...
Stock-based compensation expense...
Other current liabilities
Others
Negative Cash Flow Breakdown
Net loss
Purchases of marketable securiti...
Proceeds from exercise of stock ...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-63,200
-53,089
-46,061
-42,217
Depreciation and amortization expense
102
119
187
43
Non-cash lease expense
300
301
301
300
Non-cash interest income on marketable securities
1,221
1,273
-11,427
1,321
Stock-based compensation expense, including employee stock purchase plan expense
12,903
10,148
4,266
4,250
Prepaid expenses and other current assets
-75
-2,597
4,458
-347
Other assets and long-term deposits
668
100
496
3,911
Accounts payable
-1,905
-5,681
5,773
2,391
Other current liabilities
8,032
1,304
3,631
5,902
Operating lease liabilities
-314
-313
-313
-311
Net cash used in operating activities
-45,896
-45,987
-38,327
-34,527
Purchase of equipment
221
-
-
0
Maturities of marketable securities
89,300
74,470
91,168
88,925
Purchases of marketable securities
48,238
69,941
253,352
71,652
Net cash provided by (used in) investing activities
40,841
4,529
-162,184
17,273
Issuance of shares under at-the-market offering, net of issuance costs of 25
0
41,918
-
0
Proceeds from issuance of shares upon follow-on public offering, net of issuance costs of 13,110
-
-
205,390
-
Payment of issuance costs for shares issued under 2024 private placement
-
-
0
6,514
Proceeds from borrowings under credit facility (note 13)
-
-
0
0
Issuance costs for shares issued under november 2025 follow-on offering
-
237
-
-
Proceeds from exercise of stock options
-4,189
8,430
7,880
41
Tax withholding for stock options exercised
-
4,407
-
-
Proceeds from issuance of common stock under employee stock purchase plan
652
-
282
0
Net cash provided by (used in) financing activities
1,107
45,704
213,552
41
Net change in cash and cash equivalents
-3,948
4,246
13,041
-17,213
Cash and cash equivalents at beginning of period
52,547
48,301
35,260
139,480
Cash and cash equivalents at end of period
48,599
52,547
48,301
35,260
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Maturities of marketable
securities
$89,300K
(-45.84%↓ Y/Y)
something is missing
$4,644K
Proceeds from issuance of
common stock under...
$652K
(-12.83%↓ Y/Y)
Net cash provided by
(used in) investing...
$40,841K
(476.45%↑ Y/Y)
Net cash provided by
(used in) financing...
$1,107K
(148.21%↑ Y/Y)
Canceled cashflow
$48,459K
Canceled cashflow
$4,189K
Net change in cash
and cash...
-$3,948K
(95.46%↑ Y/Y)
Canceled cashflow
$41,948K
Stock-based compensation
expense, including...
$12,903K
(42.26%↑ Y/Y)
Other current
liabilities
$8,032K
(453.55%↑ Y/Y)
Non-cash lease expense
$300K
(-47.83%↓ Y/Y)
Depreciation and
amortization expense
$102K
(-60.77%↓ Y/Y)
Prepaid expenses and
other current assets
-$75K
(-105.74%↓ Y/Y)
Purchases of marketable
securities
$48,238K
(-72.55%↓ Y/Y)
Purchase of equipment
$221K
Proceeds from exercise of
stock options
-$4,189K
(-991.28%↓ Y/Y)
Net cash used in
operating activities
-$45,896K
(37.86%↑ Y/Y)
Canceled cashflow
$21,412K
Net loss
-$63,200K
(14.79%↑ Y/Y)
Accounts payable
-$1,905K
(46.58%↑ Y/Y)
Non-cash interest income
on marketable...
$1,221K
(-67.99%↓ Y/Y)
Other assets and
long-term deposits
$668K
(-61.57%↓ Y/Y)
Operating lease
liabilities
-$314K
(49.35%↑ Y/Y)
Buy us a coffee
Olema Pharmaceuticals, Inc. (OLMA)
Olema Pharmaceuticals, Inc. (OLMA)